Výsledky vyhledávání - "Emer O. Hanrahan"

Data from Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Autor: John V. Heymach, Bruce E. Johnson, Roy S. Herbst, Ronald B. Natale, Peter Langmuir, Sarah J. Kennedy, Helen Mann, Anderson J. Ryan, Emer O. Hanrahan

Purpose: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in progression-free survival (PFS) in advanced non-small cell lung cancer in three randomized phase II stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e8cdb505f2f2e0495deb3cb7cf1a86
https://doi.org/10.1158/1078-0432.c.6516876.v1

Zobrazit plný text záznamu

Pilot study of the implementation of G8 screening tool, cognitive screening assessment and chemotherapy toxicity assessment in older adults with cancer in a tertiary University Hospital in Ireland

Autor: Maha AlSendi, Calvin Flynn, Muhammad Raheel Khan, Paul Selvadurai, John Crown, Raymond S. McDermott, Janice Maria Walshe, David William Fennelly, Emer O. Hanrahan, Mark Doherty, Michaela Jane Higgins

Publikováno v: Journal of Clinical Oncology. 40:e24019-e24019

e24019 Background: 11% of Ireland’s population is above the age of 65. This is projected to double to 1.4 million by 2040 corresponding to doubling of cancer cases. Clinical trials often exclude patients (pts) ≥70; therefore, it can be challengin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::213482f3ddb67aedcb8ff7bf0f7074b3
https://doi.org/10.1200/jco.2022.40.16_suppl.e24019

Zobrazit plný text záznamu

Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer

Autor: Ana M. Gonzalez-Angulo, Kelly K. Hunt, Merih Güray Durak, Gabriel N. Hortobagyi, Vicente Valero, Emer O. Hanrahan, Kristine Broglio, Aysegul Sahin

Publikováno v: The Breast Journal. 17:462-469

Some patients with small (≤1.0 cm) node-negative (T1a,bN0) invasive breast cancer (IBC) who undergo only local therapy experience recurrences. There is limited information on prognostic factors in these patients. We sought to identify prognostic fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c710fe0144f1a7dab3fc374026e05512
https://doi.org/10.1111/j.1524-4741.2011.01116.x

Zobrazit plný text záznamu

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Autor: Anderson J. Ryan, Bruce E. Johnson, John V. Heymach, Ronald B. Natale, Peter Langmuir, Sarah J. Kennedy, Emer O. Hanrahan, Helen Mann, Roy S. Herbst

Publikováno v: Clinical Cancer Research. 15:3600-3609

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837edeb793a1eaca3c7f52293bfb7a36
https://doi.org/10.1158/1078-0432.ccr-08-2568

Zobrazit plný text záznamu

Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma

Autor: Gabriel N. Hortobagyi, Vicente Valero, Emer O. Hanrahan, Kristine Broglio, Roman Rouzier, Ana M. Gonzalez-Angulo, Sharon H. Giordano

Publikováno v: Journal of Clinical Oncology. 25:4952-4960

Purpose With mammographic screening, the frequency of diagnosis of stage T1a,bN0M0 breast cancer has increased. Prognosis after locoregional therapy and benefit from adjuvant systemic therapy are poorly defined. We reviewed T1a,bN0M0 breast cancer ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5715adbae08de9ab6acde9ea8b3aacd4
https://doi.org/10.1200/jco.2006.08.0499

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání